Human VKORC1 knockout HEK-293T cell line
Be the first to review this product! Submit a review
|
(0 Publication)
VKORC1 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 20 bp deletion in exon 1.
View Alternative Names
3-epoxide reductase subunit 1, EDTP308, FLJ00289, IMAGE3455200, MGC2694, MST134, MST576, Phylloquinone epoxide reductase, VKCFD2, VKOR, VKOR1_HUMAN, Vitamin K dependent clotting factors deficiency 2, Vitamin K epoxide reductase complex subunit 1, Vitamin K1 2, Vitamin K1 2,3-epoxide reductase subunit 1, Vitamin K1 epoxide reductase (warfarin sensitive)
- Sanger seq
Unknown
Sanger Sequencing - Human VKORC1 knockout HEK-293T cell line (AB266095)
Allele-2 : 1 bp insertion in exon 1.
- Sanger seq
Unknown
Sanger Sequencing - Human VKORC1 knockout HEK-293T cell line (AB266095)
Allele-1 : 20 bp deletion in exon1
Product details
Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Handling procedures
Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
VKORC1 is integral to the vitamin K cycle an essential process for activating vitamin K-dependent clotting factors. It operates within a complex with its protein partner VKORC1-like 1 (VKORC1L1). This partnership is important for maintaining effective blood coagulation. The active form of vitamin K produced by VKORC1 ensures the activity of several blood clotting factors especially factors II VII IX and X. Without proper function of VKORC1 these factors would remain inactive.
Pathways
The vitamin K cycle is where VKORC1 makes a significant impact and this cycle is vital for blood coagulation processes. Specifically VKORC1 reduces vitamin K epoxide working closely with gamma-glutamyl carboxylase (GGCX) another enzyme that modifies the glutamic acid residues on clotting factors. This modification is important for their proper functioning within the coagulation cascade. The interplay between VKORC1 and GGCX directly connects to the synthesis of active blood coagulation proteins.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
Target data
Complementary Products
![Western blot - Anti-VKORC1 antibody [EPR20245] (AB206656)](https://content.abcam.com/products/images/vkorc1-antibody-epr20245-ab206656--western-blot-img18834.jpg)
Primary Antibodies
AB249592
Anti-GGCX antibody [EPR11632] - BSA and Azide free
RabMAb|Recombinant
![Western blot - Anti-GGCX antibody [EPR11632] - BSA and Azide free (AB249592)](https://content.abcam.com/products/images/ggcx-antibody-epr11632-bsa-and-azide-free-ab249592--western-blot-img116841.jpg)
- 0
- 0
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com